Wegovy maintenance dose strategy in 2026: microdosing vs full dose

The FDA maintenance dose vs real-world prescribing

Wegovy's FDA-approved maintenance dose is 2.4mg weekly. This is the dose tested for the indication a the dose with most clinical evidence. Clinical trials demonstrated mean 14.9% weight loss at this maintenance dose over 68 weeks.

In real-world prescribing, however, many patients find 2.4mg side effects too persistent at maintenance — ongoing mild nausea, fatigue, or GI effects that don't fully resolve even after months. Their prescribers commonly step them down to a lower maintenance dose where side effects are minimal but weight loss continues.

Clinical evidence supports this approach. STEP-4 trial showed continued weight loss at 1.7mg approximately matched 2.4mg in a substantial subset of patients. STEP-2 (T2D) data confirms similar finding. The dose-response curve is not strictly linear — many patients achieve most benefit at lower-than-maximum dose.

Maintenance dose options

2.4mg (FDA-approved maximum): full dose-response, highest weight loss potential. For patients tolerating side effects and needing maximum efficacy. Recommended starting point for most patients reaching maintenance.

1.7mg: approximately 80% of 2.4mg's efficacy in trial data. Side effects substantially reduced for most patients. Increasingly common 'maintained-once-arrived' choice when patients reach their goal weight or need and tolerability compromise.

1.0mg: roughly 60% of 2.4mg's efficacy. Off-label for maintenance but clinically reasonable if higher doses unsustainable. Some long-term maintenance patients use this.

0.5mg (microdose maintenance): off-label, controversial. Some prescribers and obesity-medicine specialists use this for patients who have reached goal weight and want minimal-medication maintenance. Limited evidence but emerging clinical use.

0.25mg (microdose maintenance, extreme): occasionally used. Largely experimental approach for patients seeking absolute minimum medication exposure after reaching goal weight.

When 2.4mg makes sense

Still in active weight-loss phase. If you haven't reached your target weight and progress is continuing, stay at 2.4mg for maximum efficacy.

Side effects manageable. If 2.4mg side effects are mild and tolerable, no reason to step down.

Higher baseline weight. Patients losing larger absolute amounts often need maximum dose to maintain momentum.

Strong response history. Patients who responded well to dose escalation often benefit from staying at maximum maintenance dose.

When stepping down to 1.7mg makes sense

Persistent mild side effects at 2.4mg. Nausea, fatigue, GI issues that don't fully resolve over 2-3 months at 2.4mg are common reasons to step down.

Reached goal weight. Once at target weight, 1.7mg maintenance frequently preserves results with fewer side effects.

Plateau with good tolerability. If you've plateaued at 2.4mg, the higher dose isn't producing additional benefit — stepping down trades efficacy ceiling for tolerability gain.

Cost considerations. Wegovy pricing is dose-independent (same $1,349 retail), but if you're approaching a coverage gap or wanting to extend pen utilization, lower doses last longer per pen.

Microdose maintenance (1.0mg and below) — the off-label frontier

Not FDA-approved for weight maintenance. Limited published trial evidence. Use is increasingly common among obesity-medicine specialists and patients on long-term maintenance, particularly after reaching goal weight.

Theoretical rationale: GLP-1 receptor activity at lower doses may be sufficient to prevent the appetite rebound that drives weight regain after discontinuation. Trading some efficacy for minimal side-effect burden and lower medication exposure.

Practical considerations: lower doses last longer per pen (your $1,349 pen at 0.5mg vs 2.4mg lasts ~5x longer). This dramatically affects affordability for self-pay patients.

Risks: not enough long-term data to know whether microdose maintenance is equivalent to full-dose maintenance in preventing regain. Patients should monitor closely and step back up to higher dose if regain occurs.

Discuss with your prescriber. Microdose maintenance requires clinical judgment and monitoring — not appropriate self-direct without prescriber involvement.

Practical maintenance dose protocols

Standard transition to 1.7mg: at goal weight + 3 months at 2.4mg with stable results, step down to 1.7mg. Monitor for 4-8 weeks. If weight stable, continue. If weight starts climbing, step back up to 2.4mg.

Aggressive cost-driven step down: at goal weight, step from 2.4mg to 1.0mg directly. Monitor closely. Higher risk of regain; reserve for patients in tight budget constraints or strong response patients.

Microdose experiment: at goal weight + 6 months at 1.7mg with stable results, trial 1.0mg for 3 months. If stable, continue. If regain, step back up.

Long-term goal: minimum effective dose for weight maintenance. Trial-and-error required to find your personal threshold.